Please ensure Javascript is enabled for purposes of website accessibility

Teva: U.S. Is Investigating Copaxone, Azilect Marketing

By Associated Press – Feb 10, 2014 at 11:26AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Citi Investment Research analyst Liav Abraham said the government has been conducting more False Claims Act investigations of drug companies in recent years.

NEW YORK (AP) — Teva Pharmaceutical Industries said Monday the federal government is investigating its marketing of its multiple sclerosis drug Copaxone and Parkinson's disease treatment Azilect.

The Israeli drugmaker said the U.S. Attorney's Office for the Southern District of New York wants it to provide documents related to the marketing of the drugs from Jan. 1, 2006, to the present. It said the government is conducting a civil investigation into possible violations of the False Claims Act, a law that allows the government to collect damages reported by private citizens.

Teva Pharmaceutical Industries Ltd., the largest generic drug company in the world, also sells brand-name medications. The company reported $20.32 billion in revenue in 2013, and $4.33 billion of that total came from Copaxone, the world's biggest-selling multiple sclerosis treatment. Teva also reported $371 million in Azilect sales.

Citi Investment Research analyst Liav Abraham said the government has been conducting more False Claims Act investigations of drug companies in recent years. She said it's hard to predict how long the inquiry might last, although three to four years is typical. In many cases drug companies have paid fines to settle government investigations, but Abraham said it's not clear if Teva will do that, or how much the company would have to pay if it did so.

In 2012 Teva said the federal government was looking into allegations it paid bribes to government officials in Latin America.

The Motley Fool recommends Teva Pharmaceutical Industries. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.